ArticleAnnals of nuclear medicine2026
Development of energy deposition pixel kernel convolution for planar dosimetry in
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlanar imaging remains widely used for image-based dosimetry in 177Lu therapy due to its simplicity and fast acquisition in clinical practice. The only MIRD method is applicable to planar dosimetry. However, conventional MIRD method cannot provide accurate organ-level absorbed dose and patient-specific dose maps. This study develops a novel planar dosimetry method, the energy deposition pixel kernel (EPK) convolution, to improve accuracy of organ dose estimation and provide patient-specific energy deposition maps for planar dosimetry without a high-performance computer.
methodsEPK convolution generated the energy deposition map by convolving a pixel-based time-integrated activity map with a 2D 177Lu energy-deposition kernel incorporating a scaling factor. EPK convolution was validated in simulated two cylindrical water phantoms (containing six hot spheres of varying sizes and two overlapping hot spheres) and two digital human phantoms. EPK convolution was also applied to two open-access 177Lu -DOTATATE patients. All absorbed doses estimated from energy deposition maps incorporating partial volume effect (PVE) correction for small spheres and overlap correction (OC) for partial overlap spheres were compared with MC simulation. In case of human phantoms and patients, organ and lesion absorbed doses from patient-specific energy deposition maps incorporating OC and the conventional MIRD method were compared with MC simulation.
resultsAbsorbed dose of spheres by EPK convolution showed good agreement with those by MC simulations in both cylindrical phantom studies, with errors within 10% after applying PVE correction or OC. In the digital human phantom and two patient datasets, absorbed doses by EPK convolution were within ± 10% of MC simulation across all organs and lesions, where liver, right kidney and lesions were applied OC. In contrast, the conventional MIRD method showed larger deviations, often exceeding 10% against MC simulation.
conclusionsEPK convolution provides patient-specific energy deposition maps and improved organ or lesion dose accuracy compared with conventional MIRD method. EPK convolution may contribute for supporting personalized 177Lu therapy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.